Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated [Flag] Cybersecurity Risk Management, Strategy, and Governance [Abstract] Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block] Cybersecurity Risk Management Processes Integrated [Flag] Cybersecurity Risk Management Third Party Engaged [Flag] Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block] Cybersecurity Risk Board of Directors Oversight [Text Block] Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] Cybersecurity Risk Role of Management [Text Block] Cybersecurity Risk Management Positions or Committees Responsible [Flag] Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] Directors [Member] Geographical [Domain] Geographical [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Consolidation Items [Axis] Consolidation Items [Domain] U.S. [Member] UNITED STATES Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Additional paid-in capital Additional Paid in Capital Stock-based compensation expense Restricted Stock or Unit Expense Depreciation expense Depreciation expense Issuance of shares in consulting agreements Issuance of Stock and Warrants for Services or Claims Consolidated Balance Sheets [Abstract] Net loss per share, basic (in dollars per share) Amortization of debt discount Amortization of debt discount Cash and cash equivalents Cash and Cash Equivalent Cash Equivalents and Concentration of Cash Balance Cash and Cash Equivalents, Policy [Policy Text Block] Cash paid for interest Amount of change in valuation allowance Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Changes in operating assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Commitments and Contingencies Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Common stock, $0.00033 par value, 150,000,000 shares authorized at December 31, 2025 and December 31, 2024, 54,878,233 shares and 37,987,380 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively Common Stock, Value, Issued Current [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred Tax Expense [Abstract] Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred Tax Assets, Net [Abstract] Components of Deferred Tax Assets and Liabilities [Abstract] Income Tax Provision [Abstract] Income Tax Expense (Benefit), Continuing Operations [Abstract] Comprehensive loss Federal Current Federal Tax Expense (Benefit) Total current income tax provision Current Income Tax Expense (Benefit) Total current liabilities Liabilities, Current Current liabilities: Liabilities, Current [Abstract] State & local Current State and Local Tax Expense (Benefit) Venture Loan and Security Agreement Number of shares of common stock to be issued if converted (in shares) Face amount Face amount Effective annual interest rate Maturity date Debt Instrument, Name [Domain] Unamortized debt discount Debt Instrument, Unamortized Discount Venture Loan and Security Agreement [Abstract] Convertible Debentures [Abstract] Debt Instrument [Axis] Debt Instrument [Line Items] Schedule of Long-Term Debt Instruments [Table] Federal Deferred Federal Income Tax Expense (Benefit) Total gross deferred tax liabilities Deferred Tax Liabilities, Gross State & local Deferred State and Local Income Tax Expense (Benefit) Charitable contributions Total gross deferred tax assets Deferred Tax Assets, Gross Deferred tax assets, net Deferred Tax Assets, Net of Valuation Allowance Net operating loss Tax Carryforwards [Abstract] Deferred Tax Assets, Tax Credit Carryforwards [Abstract] R&D credits Deferred Tax Assets, Tax Credit Carryforwards, Research Stock based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Accrued expenses Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals Less valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax, net Deferred Tax Liabilities, Net Right of use asset Deferred Tax Liabilities, Leasing Arrangements Net loss per share, diluted (in dollars per share) Effective tax rate Effective Income Tax Rate Reconciliation, Percent Statutory to Effective Federal Income Tax Rate Reconciliation, Percent [Abstract] Changes in valuation allowances Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent U.S. Federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Permanent differences Meals & entertainment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Percent True-Ups Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent Current state and local income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Stock-based compensation expense Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Stock Options [Abstract] Share-Based Payment Arrangement, Additional Disclosure [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Stock-Based Compensation [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Lab Equipment [Member] Equipment [Member] Fair Value of Financial Instruments Fair Value of Financial Instruments, Policy [Policy Text Block] Finite-Lived Intangible Assets [Line Items] Furniture and Equipment [Member] Furniture and Fixtures [Member] Loss on retirement of debt Debt retirement loss General and administrative expenses General and Administrative Expense General and Administrative [Member] Consolidated Statements of Operations and Comprehensive Loss [Abstract] Accrued interest and penalties Income Taxes Income Taxes Income Tax, Policy [Policy Text Block] Statutory to Effective Federal Income Tax Rate Reconciliation, Amount [Abstract] U.S. Federal statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Meals & entertainment True-Ups Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount State and local income taxes, net of federal benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount Research and development tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Income Taxes Paid, Net [Abstract] Income taxes, net of amount refunded Income Taxes Paid, Net Nature of Operations [Abstract] Intangible Assets, Net (Excluding Goodwill) [Abstract] Interest expense Interest Expense, Debt Salaries and benefits Labor and Related Expense Total liabilities Liabilities LIABILITIES Liabilities [Abstract] Total liabilities and stockholders' equity Liabilities and Equity LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Related and Nonrelated Parties [Axis] Net cash provided by financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Cash flows from investing activities: Net cash used in operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Net loss Net loss Interest income (expense), net Nonoperating Income (Expense) [Abstract] Noncurrent assets: Assets, Noncurrent [Abstract] Noncurrent liabilities: Liabilities, Noncurrent [Abstract] Professional fees Professional Fees Net operating loss carryforwards Loss from operations Operating Income (Loss) General administrative expenses Other General and Administrative Expense Retirement Plan Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Prepaid expenses Proceeds from issuance Proceeds from issuance Proceeds from issuance of common stock, net of issuance costs Proceeds from issuance of common stock Proceeds from issuance of warrants Proceeds from issuance of secured loans Proceeds from Issuance of Secured Debt Proceeds from exercise of stock options Property and equipment Property, Plant and Equipment, Gross Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Property and Equipment [Abstract] Property and Equipment [Abstract] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Purchase of equipment Payments to Acquire Property, Plant, and Equipment Related and Nonrelated Parties [Domain] Loan principal payments Repayments of Secured Debt Research and Development Research and Development Expense, Policy [Policy Text Block] Research and Development Credit [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Sale of Stock [Domain] Aggregate number of shares purchased in securities offering (in shares) Sale of Stock, Number of Shares Issued in Transaction Offering price per share (in dollars per share) Sale of Stock, Price Per Share Net proceeds from securities offering Sale of Stock, Consideration Received on Transaction Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Property and Equipment Property, Plant and Equipment [Table Text Block] Current portion of notes payable Secured Debt, Current Note payable, net of current portion Segment Reporting Segment Reporting Disclosure [Text Block] Segment Expenses Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting Information [Line Items] Schedule of Segment Reporting Information, by Segment [Table] Granted restricted stock units (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Number of shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Shares available for grant (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Fair value of option on grant date (in dollars per share) Weighted-average grant date fair value, granted (in dollars per share) Options outstanding, aggregate intrinsic value, ending balance Options outstanding, aggregate intrinsic value, beginning balance Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Options outstanding, ending balance (in dollars per share) Options outstanding, beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Equity Award [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Changes in Stockholders' Equity [Abstract] Stock-Based Compensation Share-Based Payment Arrangement [Policy Text Block] STOCKHOLDERS' EQUITY Equity, Attributable to Parent [Abstract] Stockholders' Equity [Abstract] Stockholders' Equity Note [Abstract] Stockholders' Equity Number of shares of common stock that can be called by warrants (in shares) Number of shares of common stock that can be called by warrants (in shares) Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Sale of Stock [Axis] Subsidiary, Sale of Stock [Line Items] Supplemental information of cash and non-cash transactions: Tax credit carryforwards Tax Credit Carryforward, Amount Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward [Axis] Computer and Telephone Equipment [Member] Technology Equipment [Member] Total current assets Assets, Current Current assets: Assets, Current [Abstract] Unrecognized tax benefits Warrants to Purchase Common Stock [Member] Warrant [Member] Warrants outstanding Weighted average common shares outstanding, diluted (in shares) Weighted average common shares outstanding, basic (in shares) Common Stock [Member] Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment, Type [Domain] Research and development expenses Research and Development Expense Total assets Assets Interest income Investment Income, Interest Debt issuance costs Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Segment Expenses [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Cash and cash equivalents Statement [Table] Antidilutive Securities, Name [Domain] Convertible Debentures [Abstract] Long-Term Debt, by Current and Noncurrent [Abstract] ASSETS Assets [Abstract] Statement [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Table] Operating Loss Carryforwards [Line Items] Quoted Prices in Active Markets (Level 1) [Member] Quoted Prices in Inactive Markets (Level 2) [Member] Significant Unobservable Inputs (Level 3) [Member] Stockholders' Equity [Abstract] Fair Value of Financial Instruments Fair Value of Financial Instruments Fair Value, by Balance Sheet Grouping [Table Text Block] Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Federal [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Property and Equipment [Abstract] Property, Plant and Equipment, Net, by Type [Abstract] Issuance of warrants Adjustments to Additional Paid in Capital, Warrant Issued Operating expenses: Operating Expenses [Abstract] Total operating expenses Operating Expenses Antidilutive impact to EPS (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Per share information: Antidilutive Securities Antidilutive Security, Excluded EPS Calculation [Table] Net Loss per Common Share Earnings Per Share, Policy [Policy Text Block] Net Loss per Common Share [Abstract] Earnings Per Share, Diluted, Other Disclosure [Abstract] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Property, Plant and Equipment [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Property, Plant and Equipment, Type [Axis] Property, Plant and Equipment [Line Items] Total stockholders' equity Balance Balance Equity, Attributable to Parent Changes in valuation allowances Benefit for income taxes Net income tax benefit Net income tax benefit Income Tax Expense (Benefit) Equity Components [Axis] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Equity Component [Domain] Stock Options [Member] Stock Options to Purchase Common Stock [Member] Employee Stock Option [Member] Convertible Debentures Patent Costs Selling, General and Administrative Expenses, Policy [Policy Text Block] Issuances of common stock, net of issuance costs Stock Issued During Period, Value, New Issues Issuances of common stock from exercise of stock options Issuances of common stock, net of issuance costs (in shares) Issuance of common stock (in shares) Issuances of common stock from exercise of stock options (in shares) Segments [Axis] Amortization of issuance costs from at-the-market program Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Number of Shares [Roll Forward] Weighted Average Remaining Contractual Life and Aggregate Intrinsic Value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Vested and expected to vest, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Liquidity [Abstract] Business Combination, Consideration Transferred [Abstract] Leases [Abstract] Commitments and contingencies (Note 11) Adjustments to reconcile net loss to net cash used in operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Nature of Operations Income Tax Uncertainties [Abstract] Accrued Liabilities [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Total Accrued Liabilities, Current Accrued professional fees Accrued Professional Fees, Current Accrued rent Accrued Rent, Current Accrued interest on debt Accrued compensation Subsequent Events [Abstract] Shares Granted or Issued, Share-Based Payment Arrangement [Abstract] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Prepaid expenses and other assets Prepaid Expense and Other Assets, Current Segments [Domain] Reconciling Item [Member] Operating Segment [Member] Fair Value Hierarchy and NAV [Domain] Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Net proceeds from issuance of loan Proceeds from exercise of pre-funded warrants Transfers into Level 3 Transfers out of Level 3 Summary of Significant Accounting Policies Interest income (expenses), net Interest Income (Expense), Nonoperating Accrued Expenses [Abstract] Nature of Operations [Abstract] Balance (in shares) Balance (in shares) Shares, Outstanding Loan repayment Loan repayment Repayments of Debt Fair Value Hierarchy and NAV [Axis] Deferred Tax Assets, Net Income Tax Provision Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Statutory to Effective Federal Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Accrued Expenses Commitments and Contingencies [Abstract] Income Taxes [Abstract] Fair Value of Financial Instruments [Abstract] Subsequent Events Income Taxes Paid Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Venture Loan and Security Agreement [Abstract] Retirement Plan [Abstract] Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Assumptions Used to Value Options and Warrants Granted Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Stock-Based Compensation [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Subsequent Events Subsequent Events, Policy [Policy Text Block] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Research and Development [Member] Summary of Significant Accounting Policies [Abstract] Research and Development [Abstract] Segment Reporting [Abstract] Subsequent Events [Abstract] Fair Value Transfers Between Levels [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value 401(k) employer contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Schedule of Finite-Lived Intangible Assets [Table] Unamortized stock-based compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Weighted Average Exercise Price [Roll Forward] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Performance-Based Restricted Stock Units [Member] Performance Shares [Member] Unamortized Stock Compensation Expense [Abstract] Plan Name [Axis] Plan Name [Domain] Award Type [Axis] Subsequent Event [Member] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Domain] Additional shares authorized for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized New Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Fixed assets Intangible assets Issuance of common stock for consulting agreement Issuance of common stock for consulting agreement Issuance of common stock for licensing agreement Issuance of common stock for consulting agreement (in shares) Issuance of common stock for licensing agreement (in shares) Issuance of common stock for consulting agreement (in shares) Estimated useful lives of property and equipment Property, Plant and Equipment, Useful Life Options outstanding, weighted average remaining contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Exercisable, weighted average contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested and expected to vest, weighted average contractual life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Expected term Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Period for recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of operating segments Number of Operating Segments Number of reportable segments Number of Reportable Segments Conversion price (in dollars per share) Margin on variable rate Debt Instrument, Basis Spread on Variable Rate Fair Value of Financial Instruments [Abstract] Fair Value, Net Asset (Liability) [Abstract] Expiration date of net operating loss carryforwards Operating Loss Carryforwards, Expiration Date Other Commitments [Table] Other Commitments [Axis] Other Commitments [Domain] Other Commitments [Line Items] Commitments and Contingencies [Abstract] Other Commitments [Abstract] Fair value adjustment of warrants Fair Value Adjustment of Warrants Term of option Variable Rate [Axis] Variable Rate [Domain] Prime Rate [Member] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Domain] New Jersey [Member] New Jersey Division of Taxation [Member] Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Foreign [Member] Non-US [Member] Rent expense Future Payments for Finance Lease Liabilities [Abstract] Supplemental Cash Flow Information Related to Finance Lease [Abstract] Financing lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Finance lease liability capitalized interest rate Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Financing Lease [Abstract] Lessee, Finance Lease, Description [Abstract] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Payments of finance lease obligations Finance Lease, Principal Payments Finance lease amortization expense Remaining lease liability Finance Lease, Liability Financing lease obligation - short term Finance Lease, Liability, Current Less imputed interest Finance Lease, Liability, Undiscounted Excess Amount Financing lease obligation-long term Total future minimum lease payments Finance Lease, Liability, to be Paid 2026 Finance Lease, Liability, to be Paid, Year One 2027 Finance Lease, Liability, to be Paid, Year Two Future Payments for Financing Lease Liability Finance Lease, Liability, to be Paid, Maturity [Table Text Block] Leases Lessee, Finance Leases [Text Block] Leases Leases Lessee, Operating Leases [Text Block] Measurement Input Type [Axis] Estimated Dividend Yield [Member] Expected Term [Member] Expected Volatility [Member] Risk-free Rate [Member] Measurement Input Type [Domain] Warrants measurement input Term of financing lease Term of warrants Term of warrants Warrants and Rights Outstanding, Term Operating lease liabilities Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration] Federal State & local Effective Income Tax Rate Reconciliation, State and Local Jurisdiction, Contribution Greater than 50 Percent, Tax Effect [Extensible Enumeration] Interest expense Interest Expense, Nonoperating Cover [Abstract] Document Type Document Annual Report Document Transition Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Firm ID Auditor Location The cash inflow from issuance of pre-funded warrants with rights to purchase common shares at predetermined price. Proceeds from Issuance of Pre-funded Warrants Proceeds from issuance of pre-funded warrants The cash inflow from the additional capital contribution to the entity in connection with and At-The-Market program. Proceeds from Issuance of Common Stock, At-The-Market Program Proceeds from issuance of common stock from at-the-market program, net of issuance costs Refers to the percentage of stock outstanding as of the immediately preceding December 31st used to determine the annual increase in the Plan limit for authorized shares that may be granted as qualified and nonqualified options. Percentage of Common Stock outstanding Percentage of Common Stock outstanding used to determine annual increase in the plan limit Represents the 2010 Equity Incentive Plan, the 2012 Equity Incentive Plan, and the 2014 Equity Incentive Plan (the Plans). Equity Compensation Plans [Member] The Plans [Member] In 2014, the Company's stockholders approved the 2014 Equity Incentive Plan pursuant to which the Company may grant up to 91,367 shares as ISOs, NQs and restricted stock units ("RSUs"), subject to increases. Equity Incentive Plan 2014 [Member] 2014 Equity Incentive Plan [Member] The 2019 Inducement Plan provides for the grant of non-qualified stock options. Inducement Plan 2019 [Member] 2019 Inducement Plan [Member] In 2018, the Company's stockholders approved the 2018 Stock Incentive Plan pursuant to which the Company may grant up to 558,071 shares as (i) Stock Options, (ii) Stock Appreciation Rights, (iii) Restricted Stock, (iv) Preferred Stock, (v) Stock Reload Options and/or (vi) Other Stock-Based Awards. Equity Incentive Plan 2018 [Member] 2018 Equity Incentive Plan [Member] Incentive stock options (ISOs) under the equity compensation plans that may be granted only to employees. Incentive Stock Options [Member] Incentive Stock Options [Member] Term the Plan shall continue to remain effective, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Term of Plan Term of plan Disclosure of accounting policy for common stock warrants. Warrants, Policy [Policy Text Block] Warrants to Acquire Common Stock Disclosure of accounting policy for significant risks and uncertainties. Significant Risks and Uncertainties, Policy [Policy Text Block] Significant Risks and Uncertainties Disclosure of accounting policy for convertible debentures and embedded derivatives. Convertible Debentures, Embedded Derivatives [Policy Text Block] Convertible Debentures and Embedded Derivative Evaluation Amount of one-time up-front cash payment as consideration for the rights under the exclusive license agreement. License Agreement, Up-front Cash Payment Up-front cash payment for license agreement Number of shares issued during the period as a result of the exercise of pre-funded warrants. Stock Issued During Period, Shares, Exercise of Pre-Funded Warrants Exercise of pre-funded warrants (in shares) Value of stock issued as a result of the exercise of pre-funded warrants. Stock Issued During Period, Value, Exercise of Pre-Funded Warrants Exercise of pre-funded warrants Number of new stock issued during the period pursuant to an at-the-market program. Stock Issued During Period, Shares, New Issues, At-The-Market Program Issuance of common stock from at-the-market program, net (in shares) Amount of increase in additional paid in capital (APIC) resulting from the modification of warrants. Adjustments to Additional Paid in Capital, Modification of Warrants Modification of warrants Amount of increase in additional paid in capital (APIC) resulting from the issuance of pre-funded warrants. Adjustments to Additional Paid in Capital, Pre-Funded Warrants Issued Issuance of pre-funded warrants Equity impact of the value of new stock issued during the period pursuant to an at-the-market program. Stock Issued During Period, Value, New Issues, At-The-Market Program Issuance of common stock from at-the-market program, net On August 24, 2022, the Company, as borrower (the "Borrower"), entered into a Venture Loan and Security Agreement (the "Loan and Security Agreement") by and among Borrower, PDS Operating Corporation, as guarantor ("Guarantor", including the Borrower and any subsidiary of the Borrower party thereto from time to time, collectively, the "Loan Parties" and each individually a "Loan Party") , the persons party thereto from time to time as lenders (collectively, the "Lenders"), and Horizon Technology Finance Corporation, as a lender and collateral agent for itself and the other Lenders (in such capacity, the "Collateral Agent"). The Loan and Security Agreement provides for six separate and independent term loans. Term Loans [Member] Loan and Security Agreement [Member] Loan and Security Agreement [Member] The number of pending patent applications held by the entity. Number of pending patent applications Number of pending patent applications The number of patents held by the entity. Number of patents held Number of patents held Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options cancelled. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancellations in Period, Intrinsic Value Cancelled, aggregate intrinsic value Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options forfeited. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Intrinsic Value Forfeited, aggregate intrinsic value Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted, Weighted Average Remaining Contractual Term Granted, weighted average remaining contractual life Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options expired. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period, Intrinsic Value Expired, aggregate intrinsic value Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options granted (or share units converted) into shares. Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Intrinsic Value Granted, aggregate intrinsic value Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were cancelled. Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Cancellations in Period, Weighted Average Exercise Price Cancelled (in dollars per share) The number of shares under options that were cancelled during the reporting period. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cancellations in Period Cancelled (in shares) Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in three fiscal year and thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Finance Lease Liability To Be Paid Year Three And Thereafter 2028 and after Amount of cash outflow for principal and interest payments on finance lease. Finance Lease, Principal and Interest Payments Cash paid for finance lease liabilities Amount of lease cost recognized by lessee for finance lease contract. Finance Lease, Cost Total cost of financing leases The amount of estimated aggregate monthly rental expense under finance lease. Lessee, Finance Lease, Monthly Rental Expense Aggregate monthly rental payments The number of finance leases entered into by the lessee during the period. Lessee, Finance Lease, Number of Leases Number of financing leases entered into Liquidity and Capital Resources [Abstract] The entire disclosure of liquidity and resource matters when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). going concern. Liquidity and Capital Resources [Text Block] Liquidity and Capital Resources Securities Purchase Agreement entered into with certain purchasers in February 2025, pursuant to which the Company agreed to sell pre-funded warrants and common stock warrants to purchase shares of common stock (the February 2025 Offering). February 2025 Offering [Member] February 2025 Offering [Member] Securities Purchase Agreement entered into with certain purchasers in November 2025, pursuant to which the Company agreed to sell common stock as well as pre-funded warrants and common stock warrants to purchase shares of common stock (the November 2025 Offering). November 2025 Offering [Member] November 2025 Offering [Member] On April 30, 2025, the Company entered into a Securities Purchase Agreement (the "Securities Purchase Agreement") with certain third party lenders and JGB Collateral LLC, as collateral agent. Pursuant to the Securities Purchase Agreement, the Company agreed to sell (i) senior secured convertible debentures and (ii) warrants to purchase shares of common stock. Senior Secured Convertible Debentures [Member] Debentures [Member] Securities Purchase Agreement (the "Purchase Agreement") entered into on April 30, 2025 with certain third party lenders and JGB Collateral LLC, as collateral agent, pursuant to which the Company agreed to sell senior secured convertible debentures and warrants to purchase shares of common stock. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] In August 2024, the Company entered into an Amended and Restated At Market Issuance Sales Agreement, or the New Sales Agreement, with B. Riley Securities, Inc. and H.C. Wainwright & Co., LLC, with terms that are substantially consistent with those included in the original Sales Agreement entered into in August 2022. The New Sales Agreement superseded and replaced the Sales Agreement. Amended and Restated At Market Issuance Sales Agreement [Member] New Sales Agreement [Member] In August 2022, the Company entered into an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals. At Market Issuance Sales Agreement [Member] Sales Agreement [Member] Common stock warrants that give the holder the right to purchase shares of common stock in accordance with the terms of a Securities Purchase Agreement. Common Stock Warrants [Member] Common Stock Warrants [Member] Prefunded warrants that give the holder the right to purchase shares of common stock in accordance with the terms of a Securities Purchase Agreement. Pre-funded Warrants [Member] Pre-funded Warrants [Member] The combined purchase price per share and warrant. Combined Purchase Price Per Share and Warrant Combined purchase price per share and warrant (in dollars per share) Percentage of gross proceeds from the sale of Placement Shares sold through the Company's agents paid as a commission under an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, having an aggregate offering price of up to $50.0 million, or the Placement Shares, through or to the Agents, as sales agents or principals. Commission Percentage Commission paid on Placement Shares sold The maximum principal amount of debt that can be redeemed by the Company per calendar month. Debt Instrument, Maximum Redemption Amount Maximum redemption amount per calendar month Amount of cash inflow received from the sale of unused NOL carryforwards pursuant to the State of New Jersey's Technology Business Tax Certificate Program, which allowed certain high technology and biotechnology companies to sell unused NOL carryforwards to other New Jersey-based corporate taxpayers. Proceeds from Sale of Unused Net Operating Loss Carryforwards Proceeds from sale of tax benefits Number of shares of common stock the Company agreed to sell together with pre-funded warrants to purchase up to an aggregate of 933,334 shares of common stock, and common stock warrants to purchase up to an aggregate of 7,330,121 shares of common stock at a combined purchase price of $1.50 per share and warrant (the February 2025 Offering) pursuant to a Securities Purchase Agreement entered into with certain purchasers in February 2025. Securities Purchase Agreement, Shares to be Sold, Shares Aggregate shares to be sold (in shares) The amount of securities included in an At Market Issuance Sales Agreement, or the Sales Agreement, with B. Riley Securities, Inc. and BTIG, LLC, each an Agent and collectively the Agents, with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, or the Placement Shares, through or to the Agents, as sales agents or principals. Placement Shares, Available for future sale Placement Shares available for sale Adjustment to outstanding principal amount of Debentures used to determine the Cash Minimum to be maintained by the Company in a deposit account subject to an account control agreement as long as any portion of the Debentures remains outstanding. Adjustment to Outstanding Principal Amount of Debentures used to Determine Minimum Cash Balance Adjustment to outstanding principal amount of Debentures used to determine minimum cash balance Cash amount used to determine the Cash Minimum to be maintained by the Company in a deposit account subject to an account control agreement as long as any portion of the Debentures remains outstanding. Cash Amount used to Determine Minimum Cash Balance Cash amount used to determine minimum cash balance The number of directors participating in the Securities Purchase Offering. Number of Directors Participating in Securities Purchase Offering Number of directors participating in securities offering Cash received on stock transaction before deduction of issuance costs. Sale of Stock, Gross Consideration Received on Transaction Gross proceeds from securities offering The amount of securities included in a shelf registration statement filed with the Securities and Exchange Commission for the issuance of common stock, preferred stock, warrants, rights, debt securities and units (collectively, the "Shelf-Securities") that are available for future sale. Shelf Registration Statement, Registered Securities Registered securities in Shelf Registration Statement Carrying value as of the balance sheet date of obligations incurred through that date and payable for research and development costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Accrued Research and Development Costs, Current Accrued research and development Tabular disclosure of supplemental cash flow information related to lessee's finance leases and right-of-use assets and lease liabilities. Lessee, Finance Lease, Supplemental Cash Flow Information Related to Finance Lease [Table Text Block] Supplemental Cash Flow Information Related to Financing Lease Amount of deferred tax asset attributable to taxable temporary differences from leasing arrangements. Deferred Tax Assets, Leasing Arrangements Lease liability Amount, before allocation of a valuation allowances, of deferred tax assets attributable to the business interest expense limitation under Section 163(j) of the Internal Revenue Code. Deferred Tax Assets, Business Interest Expense Limitation 163j The total current and noncurrent amount recognized for uncertain tax positions as of the balance sheet date. Liability for Uncertain Tax Positions Uncertain tax positions Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from license agreement. Deferred Tax Assets License Agreement License agreement Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to sale of net operating losses. Effective Income Tax Rate Reconciliation, Sale of Net Operating Loss Percent State taxes/ Sale of NOL Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from research or experimental expenditures under Section 174 of the Internal Revenue Code (IRC). Deferred Tax Assets, Capitalization of Research and Development Expenses Research & development Amount of deferred tax liability attributable to taxable temporary differences from business insurance. Deferred Tax Liabilities, Business Insurance Business insurance Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws that are not subject to expiration dates. Operating Loss Carryforwards Not Subject to Expiration Net operating loss carryforwards that will carry forward indefinitely Refers to each holder of a share of common stock is entitled to number of votes for each share of common stock. Number of votes for each share of common stock Number of votes for each share of common stockholder Threshold percentage of outstanding common stock that is beneficially held. Beneficial Ownership Percentage Threshold Beneficial ownership percentage threshold Notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Notice Period Notice period Number of warrants or rights exercised during the period. Class of Warrant or Right, Exercised Warrant exercised (in shares) The combined purchase price per pre-funded warrant and warrant. Combined Purchased Price per Pre-Funded Warrant and Warrant Combined purchase price per pre-funded warrant and warrant (in dollars per share) Payments to be made upon achieving certain aggregate sales levels of the product detailed in the license agreement. Milestone payments, Achievement of Certain Aggregate Sales Levels Milestone payments for aggregate sales levels of product Royalty percentage paid on net sales of the product detailed in the license agreement. Royalty Percentage Paid on Net Sales of Product Royalty percentage paid on net sales of product Payments to be made for development and first commercial sale milestones detailed in the license agreement. Milestone payments, Development and first commercial sales Milestone payments for development and first commercial sales Period of time royalty is paid under license agreement after the first commercial sale of a product in a given country, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Term of Royalty Payment Term of royalty payment License agreements with each of the Company's executives that generally provide for product. Merck KGaA License Agreement [Member] Merck KGaA License Agreement [Member] Amount of expense for research and development classified as other. Research and Development Expense, Other Other development expenses Amount of expense associated with the process of bringing a new drug or medical device to market, including preclinical research, clinical trials, and regulatory submissions. Research and Development Expense, Clinical Clinical development expenses Single business segment for developing a growing pipeline of targeted immunotherapies designed to overcome the limitations of current immunotherapy. PDS [Member] PDS [Member] Minimum base rate to be used in computing the variable rate on the debt instrument. Debt Instrument, Minimum Variable Rate Minimum base rate used to compute floating interest rate Percentage of Company's common stock in a tender or exchange offer that would impact the conversion price of the debentures. Percentage of Common Stock in Tender or Exchange Offer Percentage of common stock in tender or exchange offer Percentage of Company's outstanding common stock acquired in a business combination or stock purchase agreement that would impact the conversion price of the debentures. Percentage of Common Stock Acquired in Business Combination or Stock Purchase Agreement Percentage of common stock acquired in business combination or stock purchase agreement